InterPAD - DETAILS

1032350-13-2, MK-2206 dihydrochloride, MK-2206 2HCl, MK2206, 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride, 8-[4-(1-AMINOCYCLOBUTYL)PHENYL]-9-PHENYL-1,2,4-TRIAZOLO[3,4-F][1,6]NAPHTHYRIDIN-3(2H)-ONE DIHYDROCHLORIDE, Q34I3E28IO, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochloride, 1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-, hydrochloride (1:2), MK-2206 HCl salt, UNII-Q34I3E28IO, C25H21N5O.2HCl, AHU377 calcium salt, MK 2206 dihydrochloride, C25H23Cl2N5O, CHEMBL4635254, SCHEMBL17100521, EX-A259, HB5934, MFCD14584463, s1078, AKOS015966903, CCG-264809, PB19401, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochl, AC-28437, AS-16298, FT-0672430, SW202557-3, P11738, J-000912, J-519356, Q27286944, (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester, 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt, 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid, 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one 2HCl

No.	Title	Href
1	MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death Dis. 2017 May 11;8(5):e2776. doi: 10.1038/cddis.2017.188.	`Click`

No.

Title

Href

MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death Dis. 2017 May 11;8(5):e2776. doi: 10.1038/cddis.2017.188.

Click

Name	MK2206
PubChem CID	46930998
Molecular Weight	480.4g/mol
Synonyms	1032350-13-2, MK-2206 dihydrochloride, MK-2206 2HCl, MK2206, 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride, 8-[4-(1-AMINOCYCLOBUTYL)PHENYL]-9-PHENYL-1,2,4-TRIAZOLO[3,4-F][1,6]NAPHTHYRIDIN-3(2H)-ONE DIHYDROCHLORIDE, Q34I3E28IO, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochloride, 1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-, hydrochloride (1:2), MK-2206 HCl salt, UNII-Q34I3E28IO, C25H21N5O.2HCl, AHU377 calcium salt, MK 2206 dihydrochloride, C25H23Cl2N5O, CHEMBL4635254, SCHEMBL17100521, EX-A259, HB5934, MFCD14584463, s1078, AKOS015966903, CCG-264809, PB19401, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochl, AC-28437, AS-16298, FT-0672430, SW202557-3, P11738, J-000912, J-519356, Q27286944, (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester, 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt, 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid, 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one 2HCl
Drug Type	Small molecule
Formula	C₂₅H₂₃Cl₂N₅O
SMILES	C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl.Cl
InChI	1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1H
InChIKey	HWUHTJIKQZZBRA-UHFFFAOYSA-N
CAS Number	1032350-13-2
ChEMBL ID	CHEMBL4635254
Toxicity	Organism	Test Type	Route(Dose)
Structure			Download 2D MOL 3D MOL

Pair Name	Bufalin, MK2206
Partner Name	Bufalin
Disease Info	[ICD-11: 2A83.1]	Plasma cell myeloma		Investigative
Gene Regulation	Up-regulation	Expression	AKT1	hsa207
In Vitro Model	NCI-H929	Plasma cell myeloma	Homo sapiens (Human)	CVCL_1600
	U266B1	Plasma cell myeloma	Homo sapiens (Human)	CVCL_0566
	LP-1	Plasma cell myeloma	Homo sapiens (Human)	CVCL_0012
	RPMI-8226	Plasma cell myeloma	Homo sapiens (Human)	CVCL_0014
Result	The data suggested that MK2206 significantly enhanced the cytocidal effects of bufalin in MM cells, regardless of the sensitivity to bortezomib, via the inhibition of the AKT/mTOR pathway. The study provided the basis of a promising treatment approach for MM.